Cited 0 time in
비대상성 간경변 환자에서 비선택적 베타 차단제: 언제부터, 언제까지?
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 이강원 | - |
| dc.contributor.author | 전대원 | - |
| dc.date.accessioned | 2022-07-15T23:52:55Z | - |
| dc.date.available | 2022-07-15T23:52:55Z | - |
| dc.date.issued | 2015-03 | - |
| dc.identifier.issn | 1598-9992 | - |
| dc.identifier.issn | 2233-6869 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157708 | - |
| dc.description.abstract | Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis | - |
| dc.format.extent | 3 | - |
| dc.language | 한국어 | - |
| dc.language.iso | KOR | - |
| dc.publisher | 대한소화기학회 | - |
| dc.title | 비대상성 간경변 환자에서 비선택적 베타 차단제: 언제부터, 언제까지? | - |
| dc.title.alternative | Nonselective β Blockers in Decompensated Cirrhosis: When to Start and for How Long | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.4166/kjg.2015.65.3.194 | - |
| dc.identifier.scopusid | 2-s2.0-85032167237 | - |
| dc.identifier.bibliographicCitation | 대한소화기학회지, v.65, no.3, pp 194 - 196 | - |
| dc.citation.title | 대한소화기학회지 | - |
| dc.citation.volume | 65 | - |
| dc.citation.number | 3 | - |
| dc.citation.startPage | 194 | - |
| dc.citation.endPage | 196 | - |
| dc.identifier.kciid | ART001972993 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.identifier.url | https://synapse.koreamed.org/articles/1007352 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
